Refine Results
  1. "Genitourinary Disease Management Team"
Formats
  1. Journal Article (3118)
  2. Meeting Abstract (956)
  3. Book Section (260)
  4. Conference Paper (31)
  5. Book Whole (18)
Groups
  1. Genitourinary Disease Management Team (4383)
  2. Surgery (2009)
  3. Solid Tumor Oncology Division (1187)
  4. Genitourinary Oncology Service (1105)
  5. Sloan Kettering Institute Faculty (962)
  6. Molecular Pharmacology and Chemistry Program Faculty (953)

More Groups

People
  1. Peter Scardino (431)
  2. Victor Reuter (383)
  3. Howard Scher (378)
  4. Robert Motzer (372)
  5. Harry Herr (319)
  6. James Eastham (298)

More People

Years
  1. 2019 (4)
  2. 2018 (123)
  3. 2017 (206)
  4. 2016 (192)
  5. 2015 (199)
  6. 2014 (218)

More Years

Publications
  1. Journal of Clinical Oncology (328)
  2. Journal of Urology (320)
  3. European Urology (209)
  4. Urology (197)
  5. International Journal of Radiation Oncology, Biology, Physics (195)
  6. BJU International (159)

More Publications

Publishers
  1. Elsevier Science, Inc. (836)
  2. Elsevier Inc. (564)
  3. American Society of Clinical Oncology (356)
  4. Nature Publishing Group (356)
  5. Wiley Blackwell (312)
  6. Springer (215)

More Publishers

Results (4383)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: Current paradigms, use of immunotherapy, and future directions
    Journal Article

    Lalani, A. K. A.; McGregor, B. A.; Albiges, L.; Choueiri, T. K.; Motzer, R.; Powles, T.; Wood, C.; Bex, A.
    European Urology (2019)

    Fulltext@MSK | Save
  • A NOMS framework solution
    Journal Article

    Nasrallah, H.; Yamada, Y.; Laufer, I.; Bilsky, M. H.
    International Journal of Radiation Oncology, Biology, Physics (2019)

    Fulltext@MSK | Save
  • Datasets for the reporting of neoplasia of the testis: Recommendations from the International Collaboration on Cancer Reporting
    Journal Article

    Berney, D. M.; Comperat, E.; Feldman, D. R.; Hamilton, R. J.; Idrees, M. T.; Samaratunga, H.; Tickoo, S. K.; Yilmaz, A.; Srigley, J. R.
    Histopathology (2019)

    Fulltext@MSK | Save
  • Non-urothelial carcinomas of the bladder
    Journal Article

    Park, S.; Reuter, V. E.; Hansel, D. E.
    Histopathology (2019)

    Fulltext@MSK | Save
  • IMmotion151: A randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Motzer, R. J.; Powles, T.; Atkins, M. B.; Escudier, B.; McDermott, D. F.; Suarez, C.; Bracarda, S.; Stadler, W. M.; Donskov, F.; Lee, J. L.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT)
    Meeting Abstract

    McHugh, D. J.; Funt, S.; Silber, D.; Knezevic, A.; Patil, S.; O'Donnell, D.; Tsai, S.; Reuter, V. E.; Sheinfeld, J.; Carver, B. S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • PSMA heterogeneity analysis in patients with metastatic castrate-resistant prostate cancer (mCRPC): Imaging versus CTCs
    Meeting Abstract

    Morris, M. J.; Vogelzang, N. J.; Sartor, A. O.; Armour, A. A.; Messmann, R. A.; Groaning, M.; Robarts, A.; Tolcher, A. W.; Gordon, M. S.; Babiker, H. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial
    Meeting Abstract

    George, D. J.; Hessel, C.; Halabi, S.; Sanford, B. L.; Michaelson, M. D.; Hahn, O. M.; Walsh, M. K.; Olencki, T.; Picus, J.; Small, E. J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC)
    Meeting Abstract

    Bellmunt, J.; De Wit, R.; Vaughn, D. J.; Fradet, Y.; Lee, J. L.; Fong, L.; Vogelzang, N. J.; Climent, M. A.; Petrylak, D. P.; Choueiri, T. K.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)
    Meeting Abstract

    Abida, W.; Bryce, A. H.; Balar, A. V.; Chatta, G. S.; Dawson, N. A.; Guancial, E. A.; Hussain, A.; Jha, G. G.; Lipsitz, D. U.; Patnaik, A.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save